AVADEL PHARMA Revenue, Profits - AVDL Annual Income Statement

Add to My Stocks
$4.5 $0.1 (2.27%) AVDL stock closing price Sep 20, 2018 (Closing)

Financial analysis of AVADEL PHARMA involves more than just checking the AVADEL PHARMA stock price, by looking at the financial statements of the company in detail. In the income statement, an investor can look at important parameters like revenue or sales, gross profits, net profits, and EPS basic to gain deeper insights. The income statement is always for an accounting period, typically for a year or quarter, and affects the stock. In this case, the AVDL stock is bound to reflect the impact of the YOY growth of 15.31%. The operating expenses as shown in the AVADEL PHARMA profit and loss statement for 2017 total to $67.42M. This line item shows that the operating expenses has decreased compared with last year. Also check: AVADEL PHARMA assets and AVADEL PHARMA free cash flow.

View revenue and profit details for latest and last 10 financial years.
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011201020092008
AVADEL PHARMA Revenues or Net Sales
173.24M150.24M173.2M14.77M22.44M26.1M32.6M37.09M42.11M38.61M
Cost Of Goods Sold (COGS)16.3M13.24M10.92M3.38M4.34M5.86M6.28M6.91M10.11M9.62M
AVADEL PHARMA Gross Profit
156.94M136.99M162.28M11.39M18.09M20.24M26.31M30.18M32M28.99M
Research & Development Expense33.41M34.61M25.6M17.29M26.68M26.11M25.08M28.68M30.41M36.24M
Selling General & Admin Expense30.36M93.46M52.66M15.69M13.3M14.15M10.81M11.33M13.33M12.91M
Income Before Depreciation Depletion Amortization93.16M8.92M84.01M-21.6M-21.89M-20.02M-9.58M-9.84M-11.75M-20.16M
Depreciation Depletion Amortization3.65M13.88M12.56M-------
Non Operating Income4.2M2.75M13.24M-65.2M-30.2M16.46M1M1.09M-1.61M
Interest Expense1.05M7.51M6.29M3.52M1.99M4.36M----
AVADEL PHARMA Pretax Income
92.66M-9.71M78.39M-90.33M-54.09M-7.93M-8.58M-8.76M-11.43M-18.56M
Provision for Income Taxes24.38M31.55M37.73M-1.4M-11.17M-4.7M----6.47M
MinorityInterest----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations68.27M-41.27M40.65M-88.92M-42.92M-3.22M-8.77M-8.97M-11.43M-12.08M
Extraordinary Items & Discontinued Operations----------
AVADEL PHARMA Profit/ Loss (Net Income)
68.27M-41.27M40.65M-88.92M-42.92M-3.22M-8.77M-8.97M-11.43M-12.08M
Average Shares used to compute Diluted EPS41.77M41.25M43.62M36.21M25.45M25.09M24.67M24.41M24.23M24.08M
Average Shares used to compute Basic EPS40.47M41.25M40.58M36.21M25.45M25.09M24.67M24.41M24.23M24.08M
Income Before Nonrecurring Items12.74M-2.59M43.1M-20.32M-8.56M-19.75M-8.77M-8.98M-11.44M-12.08M
Income from Nonrecurring Items54.51M-38.69M-2.44M-68.61M-34.37M16.46M----
AVADEL PHARMA Earnings Per Share Basic Net
1.66-1.001.00-2.34-1.69-0.13-0.37-0.37-0.47-0.50
AVADEL PHARMA Earnings Per Share Diluted Net
1.61-1.000.93-2.34-1.69-0.13-0.37-0.37-0.47-0.50
EPS Diluted Before Nonrecurring Items0.31-0.060.99-0.56-0.34-0.77-0.37-0.37-0.47-0.50
Preferred Dividends Acc Pd----------
Dividends Common----------
Dividend Per Share Common0.000.000.000.000.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

AVADEL PHARMA stock analysis involves checking at least a few of the important things like:

  • Topline: A growing topline, as seen from the AVADEL PHARMA revenue chart, as is the case with AVADEL PHARMA indicates a growing business. One needs to compare the YoY topline or sales growth of AVDL stock with its peers like CALA stock and RDHL stock to see if the growth compares well with what can be expected from a company in that industry.
  • Bottom line: The word bottom line comes because it is usually the last line of the income statement and refers to the actual profits after deducting all expenses from the revenues. AVDL stock had a healthy bottom line growth.

The income statement is also called statement of revenue and expense. The AVDL financials along with AVADEL PHARMA historical stock prices provide a lot of details about the firm.

AVADEL PHARMA Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
1.19
Dividend Yield
0%